Opendata, web and dolomites

GONDOLA SIGNED

Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GONDOLA project word cloud

Explore the words cloud of the GONDOLA project. It provides you a very rough idea of what is the project "GONDOLA" about.

peripheral    safety    people    made    neurostimulations    delivers    individuals    quality    basic    motor    hesitation    prevalence    freezing    substantial    society    induce    more    afferent    medications    2004    mechanism    reducing    neurodegenerative    symptoms    named    neurotransmitter    functioning    brain    causing    cure    undermine    central    burden    ourselves    nervous    aligned    advancing    therapies    priorities    regulate    spending    documented    disabled    skills    stages    costly    ideal    2040    pd    falls    device    time    lessening    inability    stimulation    pattern    treating    dopamine    slowness    patients    characterised    treatment    living    economic    mechanical    parkinson    portable    neurostimulation    person    annual    confidence    fluidity    disease    strategy    risk    nih    medical    10m    physical    gondolatm    amps    life    7b    double    cord    independence    invasive    points    recommendations    families    globally    movements    ninds    balance    feet    disorder    generator    body    regulates    gait    benefits    self    motions    automated    efficacy    spinal    inputs    regard    walking    clinical    effectiveness   

Project "GONDOLA" data sheet

The following table provides information about the project.

Coordinator
GONDOLA MEDICAL TECHNOLOGIES SA 

Organization address
address: CORSO ELVEZIA 9 A
city: LUGANO
postcode: 6900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gondola-parkinson.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GONDOLA MEDICAL TECHNOLOGIES SA CH (LUGANO) coordinator 50˙000.00

Map

 Project objective

Parkinson’s disease (PD) is a neurodegenerative brain disorder, characterised by the inability of a person’s brain to produce a neurotransmitter called dopamine, lessening a person’s ability to regulate body motions. PD affects 10m people globally, its prevalence is expected to double by 2040. There is no cure for PD, current therapies focus on treating symptoms that undermine patients’ quality of life. Costs associated with PD are higher than its prevalence, causing substantial economic burden on individuals, families and society. In 2004, the annual spending in Europe on PD was €10.7b. As costly as they are, these therapies improve motor symptoms in the early stages of PD, but over time, patients have more and more reduced response to medications and become more disabled. Thus, they cannot be considered as ideal with regard to efficacy, long-term effectiveness and safety. NINDS (part of the US NIH) set recommendations addressing Gait as one of the 3 top priorities for advancing basic clinical research on PD. We have aligned ourselves with NINDS’ strategy through development of GondolaTM. GondolaTM is a portable medical device made for people living with PD. It delivers a non-invasive neurostimulation treatment named Automated Mechanical Peripheral Stimulation (AMPS). It is based on physical neurostimulations of specific points in both feet, which allow to increase the afferent inputs from the peripheral nervous system to the spinal cord, and induce a better functioning of the central pattern generator (the mechanism that regulates movements in the body). Four clinical studies have documented that AMPS is effective in improving motor skills in PD, particularly slowness of movements and freezing of gait. Users have derived the following benefits from the device: Reduced Freezing of gait, gait hesitation, slowness of movements, improved independence, self-confidence, fluidity in walking and balance, reducing the risk of falls and improving the quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GONDOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GONDOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

AUTHEVOO (2019)

DNA-Authenticity & Traceability for Extra Virgin Olive Oil: Τrust the DNA, the label.

Read More